192 related articles for article (PubMed ID: 20393311)
1. Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease.
Colaianni A; Chandrasekharan S; Cook-Deegan R
Genet Med; 2010 Apr; 12(4 Suppl):S5-S14. PubMed ID: 20393311
[TBL] [Abstract][Full Text] [Related]
2. Gene patents and licensing: case studies prepared for the Secretary's Advisory Committee on Genetics, Health, and Society.
Cook-Deegan R; Heaney C
Genet Med; 2010 Apr; 12(4 Suppl):S1-2. PubMed ID: 20393303
[TBL] [Abstract][Full Text] [Related]
3. Ethical Issues with Genetic Testing for Tay-Sachs.
Clayton T
J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
[TBL] [Abstract][Full Text] [Related]
4. Carrier testing for autosomal-recessive disorders.
Vallance H; Ford J
Crit Rev Clin Lab Sci; 2003 Aug; 40(4):473-97. PubMed ID: 14582604
[TBL] [Abstract][Full Text] [Related]
5. Population-specific screening by mutation analysis for diseases frequent in Ashkenazi Jews.
DeMarchi JM; Caskey CT; Richards CS
Hum Mutat; 1996; 8(2):116-25. PubMed ID: 8844209
[TBL] [Abstract][Full Text] [Related]
6. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
Kronn D; Jansen V; Ostrer H
Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
[TBL] [Abstract][Full Text] [Related]
7. Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent.
Kalman L; Wilson JA; Buller A; Dixon J; Edelmann L; Geller L; Highsmith WE; Holtegaard L; Kornreich R; Rohlfs EM; Payeur TL; Sellers T; Toji L; Muralidharan K
J Mol Diagn; 2009 Nov; 11(6):530-6. PubMed ID: 19815695
[TBL] [Abstract][Full Text] [Related]
8. Tay-Sachs Carrier Screening by Enzyme and Molecular Analyses in the New York City Minority Population.
Mehta N; Lazarin GA; Spiegel E; Berentsen K; Brennan K; Giordano J; Haque IS; Wapner R
Genet Test Mol Biomarkers; 2016 Sep; 20(9):504-9. PubMed ID: 27362553
[TBL] [Abstract][Full Text] [Related]
9. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program.
Rozenberg R; Pereira Lda V
Sao Paulo Med J; 2001 Jul; 119(4):146-9. PubMed ID: 11500789
[TBL] [Abstract][Full Text] [Related]
10. ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent.
ACOG Committee on Genetics
Obstet Gynecol; 2004 Aug; 104(2):425-8. PubMed ID: 15292027
[TBL] [Abstract][Full Text] [Related]
11. Results of the College of American Pathology/American College of Medical Genetics and Genomics external proficiency testing from 2006 to 2013 for three conditions prevalent in the Ashkenazi Jewish population.
Feldman GL; Schrijver I; Lyon E; Palomaki GE;
Genet Med; 2014 Sep; 16(9):695-702. PubMed ID: 24577267
[TBL] [Abstract][Full Text] [Related]
12. Screening for Tay-Sachs disease carriers by full-exon sequencing with novel variant interpretation outperforms enzyme testing in a pan-ethnic cohort.
Cecchi AC; Vengoechea ES; Kaseniit KE; Hardy MW; Kiger LA; Mehta N; Haque IS; Moyer K; Page PZ; Muzzey D; Grinzaid KA
Mol Genet Genomic Med; 2019 Aug; 7(8):e836. PubMed ID: 31293106
[TBL] [Abstract][Full Text] [Related]
13. Canavan disease: diagnosis and molecular analysis.
Matalon R
Genet Test; 1997; 1(1):21-5. PubMed ID: 10464621
[TBL] [Abstract][Full Text] [Related]
14. Improving accuracy of Tay Sachs carrier screening of the non-Jewish population: analysis of 34 carriers and six late-onset patients with HEXA enzyme and DNA sequence analysis.
Park NJ; Morgan C; Sharma R; Li Y; Lobo RM; Redman JB; Salazar D; Sun W; Neidich JA; Strom CM
Pediatr Res; 2010 Feb; 67(2):217-20. PubMed ID: 19858779
[TBL] [Abstract][Full Text] [Related]
15. Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.
Cook-Deegan R; DeRienzo C; Carbone J; Chandrasekharan S; Heaney C; Conover C
Genet Med; 2010 Apr; 12(4 Suppl):S15-38. PubMed ID: 20393305
[TBL] [Abstract][Full Text] [Related]
16. Heterozygote screening for Tay-Sachs disease: past successes and future challenges.
Natowicz MR; Prence EM
Curr Opin Pediatr; 1996 Dec; 8(6):625-9. PubMed ID: 9018448
[TBL] [Abstract][Full Text] [Related]
17. Carrier screening for Canavan disease in Australia.
Howell VM; Proos AL; LaRue D; Jensen CH; Beach F; Burnett L
J Inherit Metab Dis; 2004; 27(2):289-90. PubMed ID: 15243987
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection of fetal Mendelian disorders: Tay-Sachs disease.
Guetta E; Peleg L
Methods Mol Biol; 2008; 444():147-59. PubMed ID: 18425478
[TBL] [Abstract][Full Text] [Related]
19. Carrier screening panels for Ashkenazi Jews: is more better?
Leib JR; Gollust SE; Hull SC; Wilfond BS
Genet Med; 2005 Mar; 7(3):185-90. PubMed ID: 15775754
[TBL] [Abstract][Full Text] [Related]
20. Prenatal Diagnosis of Tay-Sachs Disease.
Zhang J; Chen H; Kornreich R; Yu C
Methods Mol Biol; 2019; 1885():233-250. PubMed ID: 30506202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
